Found 4374 articles for: ""
Severe Reaction to 5% Imiquimod Cream with Excellent Clinical and Cosmetic Outcomes
April 2007 | Volume 6 | Issue 4 | Case Reports | 452 | Copyright © April 2007
Imiquimod, an immune response modifier approved for the treatment of external genital warts, actinic keratoses, and superficial basal cell carcinoma, can induce a severe local inflammatory response. ...
Read MoreMyeloid Sarcoma Presenting as an Isolated Nodule in a Patient with Acute Myelogenous Leukemia
April 2007 | Volume 6 | Issue 4 | Case Reports | 447 | Copyright © April 2007
We report a case of an elderly female in remission from acute myelogenous leukemia that presented with a nonhealing enlarging asymptomatic nodule on her right thigh. A wide excision of the nodule and...
Read MorePositive Impact of Chloroquine on Delayed Pressure Urticaria
April 2007 | Volume 6 | Issue 4 | Case Reports | 445 | Copyright © April 2007
Delayed pressure urticaria (DPU) is characterized by swellings that develop at sites of sustained pressure on the skin several hours after the pressure is removed and can persist for days. DPU is gen...
Read MoreNovel Use of 308-nm Excimer Laser to Treat a Primary Cutaneous CD30+ Lymphoproliferative Nodule
April 2007 | Volume 6 | Issue 4 | Case Reports | 440 | Copyright © April 2007
CD30+ cutaneous lymphoproliferative disorders, the second most common cutaneous T cell lymphoma after mycosis fungoides, represent a spectrum of conditions ranging from lymphomatoid papulosis to bord...
Read MorePæcilomyces Lilacinus Infection with a Sporotrichoid Pattern in a Renal Transplant Patient
April 2007 | Volume 6 | Issue 4 | Case Reports | 436 | Copyright © April 2007
Pæcilomyces lilacinus (P. lilacinus) is a saprophytic fungus with increasing prevalence as a source of infection in the immunosuppressed patient population. We report a P. lilacinus infection with a...
Read MoreCalcitriol 3µg/g Ointment in the Management of Mild to Moderate Plaque Type Psoriasis: Results from 2 Placebo-Controlled, Multicenter, Randomized Double-Blind, Clinical Studies
April 2007 | Volume 6 | Issue 4 | Original Article | 428 | Copyright © April 2007
Background: Psoriasis is a chronic skin disorder affecting approximately 2% of the US population. Psoriasis may occur anywhere on the body with initial presentation usually seen between 15 and 30 yea...
Read MoreAn Open-Label Study to Evaluate the Transition of Patients with Chronic Plaque Psoriasis from Cyclosporine to Alefacept
April 2007 | Volume 6 | Issue 4 | Original Article | 424 | Copyright © April 2007
Eleven patients with well-controlled psoriasis on cyclosporine (Physician’s Global Assessment [PGA] of “mild” or better) participated in an open-label study that evaluated a strategy for transi...
Read MoreA Multiple-Domain Framework of Clinical, Economic, and Patient-Reported Outcomes for Evaluating Benefits of Intervention in Atopic Dermatitis
April 2007 | Volume 6 | Issue 4 | Original Article | 416 | Copyright © April 2007
Atopic dermatitis (AD) increases health care utilization, affects patient quality of life, places a burden on caregivers, decreases patient/parent productivity, and adds to health care costs. Few stu...
Read MoreInternational Guidelines for Effective Control of Head Louse Infestations
April 2007 | Volume 6 | Issue 4 | Original Article | 409 | Copyright © April 2007
Head louse infestations are increasing or remain high in most countries. In order to reduce the proportion of children infested with head lice and slow down the emergence of strains of lice resistant ...
Read MoreSuppressive Therapy versus Episodic Therapy with Oral Valacyclovir for Recurrent Herpes Labialis: Efficacy and Tolerability in an Open-Label, Crossover Study
April 2007 | Volume 6 | Issue 4 | Original Article | 400 | Copyright © April 2007
Oral valacyclovir’s efficacy and tolerability as suppressive therapy versus episodic therapy were compared for recurrent herpes labialis (RHL). Subjects with a history of at least 3 RHL episodes in...
Read MoreHeat-Shock Proteins as Drugs: Potential Applications in Cancer, Infections, and Autoimmune and Atopic Diseases
April 2007 | Volume 6 | Issue 4 | Original Article | 393 | Copyright © April 2007
Heat-shock proteins (HSPs) serve as both a valuable target as well as a potent tool in the therapy of melanoma and human papillomavirus infections. HSPs have been found to associate with key pathogen...
Read MoreNonsurgical Tightening of Skin Laxity: A New Radiofrequency Approach
April 2007 | Volume 6 | Issue 4 | Original Article | 381 | Copyright © April 2007
Background: Improvement in skin laxity can be difficult to achieve without invasive surgical procedures. Monopolar radiofrequency (RF) treatment is used by physicians to heat skin and promote tissue ...
Read MoreCytokine Therapy in Advanced Melanoma
April 2007 | Volume 6 | Issue 4 | Original Article | 374 | Copyright © April 2007
Patients with melanoma considered at high risk for recurrence or regional metastases often have to choose between adjuvant interferon therapy or enrolling in a clinical trial. High-dose interleukin-2...
Read MoreClinical Trial Review
June 2007 | Volume 6 | Issue 6 | Features | 671 | Copyright © June 2007
Pipeline Previews
June 2007 | Volume 6 | Issue 6 | Features | 669 | Copyright © June 2007
News, Views, And Reviews
June 2007 | Volume 6 | Issue 6 | Features | 665 | Copyright © June 2007
Lit Review (New!)
June 2007 | Volume 6 | Issue 6 | Features | 662 | Copyright © June 2007
Clearance of Lentigines in Japanese Men with the Long-Pulsed Alexandrite Laser
June 2007 | Volume 6 | Issue 6 | Case Reports | 653 | Copyright © June 2007
Background: 5-fluorouracil (5-FU) and imiquimod creams are accepted topical therapies for actinic keratosis (AK). Both are associated with a prolonged course of treatment with an inflammatory respons...
Read MoreEfalizumab-Associated Lymphoproliferative Disease
June 2007 | Volume 6 | Issue 6 | Case Reports | 646 | Copyright © June 2007
Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development...
Read MoreCombined Effect of Anti-inflammatory Dose Doxycycline (40-mg Doxycycline, USP Monohydrate Controlled-Release Capsules) and Metronidazole Topical Gel 1% in the Treatment of Rosacea
June 2007 | Volume 6 | Issue 6 | Original Article | 641 | Copyright © June 2007
Research into the pathophysiology of rosacea suggests a central role for inflammatory mediators such as nitric oxide (NO), reactive oxygen species (ROS), and matrix metalloproteinases (MMPs). Effectiv...
Read More
